Understanding how TRIP13 contributes to radiation resistance in oral cancer

Elucidating the Molecular Mechanism of TRIP13-mediated Radiation Resistance in Oral Squamous Cell Carcinoma

NIH-funded research University of Michigan at Ann Arbor · NIH-11080749

This study is looking at a protein called TRIP13 that helps some oral cancer cells survive radiation treatment, and by understanding how it works, the researchers hope to find ways to make these tumors more responsive to radiation, which could lead to better treatment options for patients.

Quick facts

Grant typeFellowship grant
Study typeNIH-funded research
Funding institutionUniversity of Michigan at Ann Arbor NIH-funded
Lab location1 site (Ann Arbor, United States)
Project IDNIH-11080749 on NIH RePORTER

What this research studies

This research investigates the role of TRIP13, a protein that helps cancer cells repair damage caused by radiation, in oral squamous cell carcinoma (OSCC). By exploring the molecular mechanisms behind TRIP13's function, the study aims to uncover why some tumors resist radiation treatment, which is a common therapy for OSCC. The researchers will focus on how TRIP13 interacts with DNA repair processes, particularly the non-homologous end joining pathway, to enhance the survival of cancer cells after radiation exposure. This understanding could lead to new strategies that make tumors more sensitive to radiation, potentially improving treatment outcomes for patients.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with oral squamous cell carcinoma who are undergoing radiation therapy.

Not a fit: Patients with other types of cancers or those not receiving radiation therapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved radiation therapies for patients with oral squamous cell carcinoma, enhancing treatment effectiveness and reducing tumor recurrence.

How similar studies have performed: Previous research has shown that targeting DNA repair mechanisms can enhance the effectiveness of radiation therapy, suggesting that this approach may yield promising results.

Where this research is happening

Ann Arbor, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Cancers
Last reviewed 2026-06-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.